369 related articles for article (PubMed ID: 34525891)
1. COVID-19 and oral diseases: Assessing manifestations of a new pathogen in oral infections.
Naqvi AR; Schwartz J; Brandini DA; Schaller S; Hussein H; Valverde A; Naqvi RA; Shukla D
Int Rev Immunol; 2022; 41(4):423-437. PubMed ID: 34525891
[TBL] [Abstract][Full Text] [Related]
2. Covid-19 and oral diseases: Crosstalk, synergy or association?
Brandini DA; Takamiya AS; Thakkar P; Schaller S; Rahat R; Naqvi AR
Rev Med Virol; 2021 Nov; 31(6):e2226. PubMed ID: 33646645
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
4. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
5. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
6. Immunological and Hematological Response in COVID-19.
Słomka A; Martucci G; Raffa GM; Malvindi PG; Żekanowska E; Lorusso R; Suwalski P; Kowalewski M
Adv Exp Med Biol; 2021; 1352():73-86. PubMed ID: 35132595
[TBL] [Abstract][Full Text] [Related]
7. Oral Lesions Associated with COVID-19 and the Participation of the Buccal Cavity as a Key Player for Establishment of Immunity against SARS-CoV-2.
Gutierrez-Camacho JR; Avila-Carrasco L; Martinez-Vazquez MC; Garza-Veloz I; Zorrilla-Alfaro SM; Gutierrez-Camacho V; Martinez-Fierro ML
Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141654
[TBL] [Abstract][Full Text] [Related]
8. Oral manifestations of Covid-19-A literature review.
Farid H; Khan M; Jamal S; Ghafoor R
Rev Med Virol; 2022 Jan; 32(1):e2248. PubMed ID: 34028129
[TBL] [Abstract][Full Text] [Related]
9. Oral manifestations in a patient with a history of asymptomatic COVID-19: Case report.
Corchuelo J; Ulloa FC
Int J Infect Dis; 2020 Nov; 100():154-157. PubMed ID: 32882435
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 manifestation in the oral cavity - a narrative literature review.
Kusiak A; Cichońska D; Tubaja M; Skorek A; Jereczek-Fossa BA; Corrao G; Marvaso G; Alterio D
Acta Otorhinolaryngol Ital; 2021 Oct; 41(5):395-400. PubMed ID: 34734574
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Infection and Significance of Oral Health Management in the Era of "the New Normal with COVID-19".
Imai K; Tanaka H
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207046
[TBL] [Abstract][Full Text] [Related]
13. Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the
López-Iranzo FJ; López-Rodas AM; Franco L; López-Rodas G
Curr Pharm Des; 2020; 26(35):4515-4521. PubMed ID: 32787748
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody therapy in COVID-19.
Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
17. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
18. Estimating the viral loads of SARS-CoV-2 in the oral cavity when complicated with periapical lesions.
Altaie AM; Hamdy R; Venkatachalam T; Hamoudi R; Soliman SSM
BMC Oral Health; 2021 Nov; 21(1):567. PubMed ID: 34749700
[TBL] [Abstract][Full Text] [Related]
19. A consideration of publication-derived immune-related associations in Coronavirus and related lung damaging diseases.
Geifman N; Whetton AD
J Transl Med; 2020 Aug; 18(1):297. PubMed ID: 32746922
[TBL] [Abstract][Full Text] [Related]
20. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
